Evaluating gene therapy effects on multiple myeloma cells from patient samples
Study for Validation of Target Therapy in Multiple Myeloma Cells From Patients With miRNAs Released From B Cells, and Study of the Bone Marrow Tumor Microenvironment (Microenvironment of MM)
Centro di Riferimento Oncologico - Aviano · NCT06154317
This study is testing a new gene therapy on multiple myeloma cells taken from patients to see if it can help treat the disease better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centro di Riferimento Oncologico - Aviano (other) |
| Locations | 1 site (Aviano, Pordenone) |
| Trial ID | NCT06154317 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on multiple myeloma, a hematologic cancer characterized by the clonal expansion of plasma cells. It aims to assess the impact of gene therapy identified in laboratory settings on primary tumor cells obtained from patients. By examining the interaction between myeloma cells and the bone marrow microenvironment, the study seeks to develop strategies that target multiple aspects of the disease, including proliferation and metastasis. The research will utilize patient-derived samples to translate laboratory findings into potential therapeutic applications.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have been diagnosed with multiple myeloma and are scheduled for a bone marrow biopsy.
Not a fit: Patients who do not have adequate bone marrow biopsy material or cannot provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to new therapeutic strategies that improve treatment outcomes for patients with multiple myeloma.
How similar studies have performed: While there have been studies exploring gene therapy in hematologic cancers, this specific approach focusing on the microenvironment of multiple myeloma is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age≥18 years; * Diagnosis of multiple myeloma for which a bone marrow biopsy is scheduled for practice * Patients able to express appropriate consent to participation in the study (e.g., able to understand Italian, patient with intact cognitive abilities). Exclusion Criteria: * Absence of signed informed consent form * Inadequate or insufficient bone marrow biopsy material
Where this trial is running
Aviano, Pordenone
- Centro di Riferimento Oncologico (CRO) di Aviano - IRCCS — Aviano, Pordenone, Italy (RECRUITING)
Study contacts
- Principal investigator: Mariagrazia Michieli, MD — Centro di Riferimento Oncologico (CRO) di Aviano-IRCCS
- Study coordinator: Mariagrazia Michieli, MD
- Email: mmichieli@cro.it
- Phone: 0434 659 020
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Multiple Myeloma